Discovery of Fused Triazolo-thiadiazoles as Inhibitors of TNF-alpha: Pharmacophore Hybridization for Treatment of Neuropathic Pain

Pain and Therapy

Volumn 1, Issue 1, 2012, Pages

  Sharma, Monika ^a   Deekshith, Vanamala ^a   Semwal, Arvind ^a   Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

2 Diphenyl 1 picrylhydrazyl; Antiallodynic; Antihyperalgesic; Neuropathic pain; Nitric oxide; TNF alpha; Triazolo thiadiazole

Indexed keywords

EID: 85110326130     PISSN: 21938237     EISSN: 2193651X     Source Type: Journal    
DOI: 10.1007/s40122-012-0003-6     Document Type: Article

References (44)

1. Yogeeswari Y, Ragavendran JV, Sriram D. Neuropathic pain: strategies in drug discovery and treatment. Expert Opin Drug Discov. 2007;2:169–84. DOI: 10.1517/17460441.2.2.169
2. Sommer C, Galbraith JA, Heckman HM, Myers RR. Pathology of experimental compression neuropathy producing hyperesthesia. J Neuropathol Exp Neurol. 1993;52:223–33. DOI: 10.1097/00005072-199305000-00006
3. Frisen J, Risling M, Fried K. Distribution and axonal relations of macrophages in a neuroma. Neuroscience. 1993;55:1003–13. DOI: 10.1016/0306-4522(93)90314-6
4. Cunha FQ, Poole S, Lorenzetti B, Ferreira SH. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol. 1992;107:660–4. DOI: 10.1111/j.1476-5381.1992.tb14503.x
5. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol. 1997;121:417–24. DOI: 10.1038/sj.bjp.0701148
6. Shubayev VI, Myers RR. Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res. 2000;855:83–9. DOI: 10.1016/S0006-8993(99)02321-5
7. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience. 1996;73:625–9. DOI: 10.1016/0306-4522(96)00127-3
8. Ignatowski TA, Covey WC, Knight PR, Severin CM, Nickola TJ, Spengler RN. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 1999;841:70–7. DOI: 10.1016/S0006-8993(99)01782-5
9. Padi SS, Kulkarni SK. Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms. Eur J Pharmacol. 2008;601:79–87. DOI: 10.1016/j.ejphar.2008.10.018
10. Naik AK, Tandan SK, Dudhgaonkar SP, et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-l-cysteine in rats. Eur J Pain. 2006;10:573–9. DOI: 10.1016/j.ejpain.2005.08.006
11. Sommer C, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain. 1998;74:83–91. DOI: 10.1016/S0304-3959(97)00154-1
12. Sommer C, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001;913:86–9. DOI: 10.1016/S0006-8993(01)02743-3
13. Chapleo CB, Myers PL, Smith AC, Tulloch IF, Turner S, Walter DS. Substituted 1,3,4-thiadiazoles with anticonvulsant activity. 3. Guanidines. J Med Chem. 1987;30:951–4. DOI: 10.1021/jm00388a038
14. Schenone S, Brullo C, Bruno O, et al. New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities. Bioorg Med Chem. 2006;14:1698–705. DOI: 10.1016/j.bmc.2005.10.064
15. Clerici F, Pocar D, Guido M, Loche A, Perlini V, Brufani M. Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity. J Med Chem. 2001;44:931–6. DOI: 10.1021/jm001027w
16. Boschelli DH, Connor DT, Bornemeier DA, et al. 1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities. J Med Chem. 1993;36:1802–10. DOI: 10.1021/jm00065a002
17. Carroll WA, Kalvin DM, Perez Medrano A, et al. Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists. Bioorg Med Chem Lett. 2007;17:4044–8. DOI: 10.1016/j.bmcl.2007.04.075
18. Florjancic AS, Peddi S, Perez Medrano A, et al. Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-1H-1,2,4-triazol-5-amine and 4-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X7 antagonists. Bioorg Med Chem Lett. 2008;18:2089–92. DOI: 10.1016/j.bmcl.2008.01.095
19. Chakravarty PK, Zuegner LL, Parsons WH, et al. Biaryl substituted triazoles as sodium channel blockers. US Patent 7,572,822.
20. Alberto DZ, Nadine J, Maria Pillar GJ, Maria Rosa CA, Jose CM. 1,2,4-Triazole derivatives as sigma receptor inhibitors. European Patent 1,921,073.
21. Jagerovic N, Hernandez-Folgado L, Alkorta I, et al. Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1 h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem. 2004;47:2939–42. DOI: 10.1021/jm031099y
22. Lange JH, van Stuivenberg HH, Coolen HK, et al. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem. 2005;48:1823–38. DOI: 10.1021/jm040843r
23. Yogeeswari P, Ragavendran JV, Sriram D, et al. Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach. J Med Chem. 2007;50:2459–67. DOI: 10.1021/jm061431g
24. Yogeeswari P, Sriram D, Thirumurugan R, et al. Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. J Med Chem. 2005;48:6202–11. DOI: 10.1021/jm050283b
25. Yogeeswari P, Sriram D, Saxena A, Thirumurugan R, Stables J. 2,4-Dimethoxyphenylsemicarbazones with anticonvulsant activity against three animal models of seizures: synthesis and pharmacological evaluation. Bioorg Med Chem. 2006;14:3106–12. DOI: 10.1016/j.bmc.2005.12.041
26. Yogeeswari P, Sriram D, Mehta S, et al. Anticonvulsant and neurotoxicity evaluation of some 6-substituted benzothiazolyl-2-thiosemicarbazones. Farmaco. 2005;60:1–5. DOI: 10.1016/j.farmac.2004.09.001
27. Shalini M, Yogeeswari P, Sriram D, Stables JP. Cyclization of the semicarbazone template of aryl semicarbazones: synthesis and anticonvulsant activity of 4,5-diphenyl-2H-1,2,4-triazol-3(4H)-one. Biomed Pharmacother. 2009;63:187–93. DOI: 10.1016/j.biopha.2006.04.002
28. Song Y, Connor DT, Sercel AD, et al. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. J Med Chem. 1999;42:1161–9. DOI: 10.1021/jm980570y
29. Palaska E, Sahin G, Kelicen P, Durlu NT, Altinok G. Synthesis and anti-inflammatory activity of 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones. Farmaco. 2002;57:101–7. DOI: 10.1016/S0014-827X(01)01176-4
30. Amir M, Shikha K. Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2,6-dichloroanilino) phenyl]acetic acid derivatives. Eur J Med Chem. 2004;39:535–45. DOI: 10.1016/j.ejmech.2004.02.008
31. Receveur JM, Bryans JS, Field MJ, Singh L, Horwell DC. Synthesis and biological evaluation of conformationally restricted gabapentin analogues. Bioorg Med Chem Lett. 1999;9:2329–34. DOI: 10.1016/S0960-894X(99)00383-2
32. Yogeeswari P, Sriram D, Reddy ASK, Semwal A, Mishra R. Newer 4-aminobutyric acid derivatives for the treatment of epilepsy and neuropathic pain. Indian Patent Application No. 1138/CHE/2009 A (18/5/2009).
33. Dunham NW, Miya TA. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Sci Eds. 1957;46:208–9. DOI: 10.1002/jps.3030460322
34. Siegmund EA, Cadmus RA, Lu G. A method for evaluating both nonnarcotic and narcotic analgesics. Proc Soc Exp Biol. 1957;95:729–31.
35. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987;30:103–14. DOI: 10.1016/0304-3959(87)90088-1
36. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107. DOI: 10.1016/0304-3959(88)90209-6
37. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205–18. DOI: 10.1016/0304-3959(90)91074-S
38. Garth T, Whiteside JH, Jamie B, et al. Pharmacological characterisation of a rat model of incisional pain. Br J Pharmacol. 2004;141:85–91. DOI: 10.1038/sj.bjp.0705568
39. Harris JM, Spencer PS. A modified plethysmographic apparatus for recording volume changes in the rat paw. J Pharm Pharmacol. 1962;14:464–6. DOI: 10.1111/j.2042-7158.1962.tb11125.x
40. Sekut L, Yarnall D, Stimpson SA, et al. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol. 1995;100:126–32. DOI: 10.1111/j.1365-2249.1995.tb03613.x
41. Mellors A, Tappel AL. The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol. J Biol Chem. 1966;241:4353–6.
42. Coderre TJ, Melzack RJ. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci. 1992;12:3665–70.
43. Okuda K, Sakurada C, Takahashi M, Yamada T, Sakurada T. Characterization of nociceptive responses and spinal releases of nitric oxide metabolites and glutamate evoked by different concentrations of formalin in rats. Pain. 2001;92:107–15. DOI: 10.1016/S0304-3959(00)00476-0
44. Da Silva KA, Manjavachi MN, Paszcuk AF, et al. Plant derived alkaloid (-)-cassine induces anti-inflammatory and anti-hyperalgesics effects in both acute and chronic inflammatory and neuropathic pain models. Neuropharmacology. 2011;62:967–77. DOI: 10.1016/j.neuropharm.2011.10.002